Thabor Therapeutics’s website
1 known investors
Thabor Therapeutics is an INSERM spin-off developing a first-in-class therapeutic antibody that targets extracellular AGR2 to treat inflammatory mucosal diseases. Its non-immunosuppressive approach aims to restore epithelial homeostasis by preventing inflammation, fibrosis, and loss of epithelial integrity.